ASH Selects Next Congressional Fellow
Jerome Seid, MD, has been selected by the American Society of Hematology (ASH) to be the next ASH Congressional Fellow. Dr. Seid, a hematologist/oncologist at Great Lakes Cancer Management Specialists in southeastern Michigan, will spend the 2020-2021 academic year in Washington, DC, where he will help shape health-care and hematology policy in a congressional office.
Dr. Seid has policy interests in palliative care and oral chemotherapy parity. He previously served as President of the Michigan Society of Hematology and Oncology and will continue to refine his advocacy skills with the goal of bringing the practitioner perspective to governance.
Established in 2016, the ASH Congressional Fellowship aims to educate members about the policymaking process, including Congress’ relationship to the hematology community, while educating Congressional members and staff about hematology.
Learn more on the ASH website.
2020 Editor for ASH News Daily Announced
Ahmar Zaidi, MD, has been selected as the next Editor of ASH News Daily, the official publication of the ASH Annual Meeting. Dr. Zaidi is a pediatric hematologist with a focus on sickle cell disease, cytopenias, hemoglobinopathies, and nonmalignant hematologic disorders, and is a Clinical Assistant Professor at Wayne State University in Detroit, Michigan. His other research interests include social media and wearable technology. Dr. Zaidi previously served as both an author for ASH News Daily and was selected to participate in the ASH Medical Educators Institute in 2019.
Learn more about ASH News Daily here.
ASH COVID-19 Research Agenda for Hematology
COVID-19 is not just a pulmonary disease; it can have severe hematologic complications as well, and the pandemic is complicating the care of patients with pre-existing hematologic disorders. In response, ASH has developed the COVID-19 Research Agenda in Hematology. It explores the key underlying research questions that, to date, lack scientific evidence to inform clinical practice and treatment efforts. The Society believes that answers to these research questions are of utmost importance to better understand the biology of COVID-19 and the interaction of the virus with underlying hematologic conditions. As we better understand COVID-19 and the hematologic implications of this infection, new questions will undoubtedly arise and ASH will continue to revisit and update the agenda.
Topics addressed in the agenda thus far include:
- Coagulation, thrombosis, and COVID-19
- Epidemiology and health disparities
- Hematologic malignancies and COVID-19
- Impact of hematopoiesis and hematopoietic dysfunction on COVID-19 infection and illness
- Inflammatory signaling, cytokine release, and COVID-19 disease
- Transfusion medicine and convalescent plasma
Find the COVID-19 Research Agenda for Hematology here.
Get Ready for the ASH Meeting on Hematologic Malignancies: A Virtual Experience!
During the COVID-19 pandemic, ASH is focused on the well-being of the hematology community while striving to continue to provide important education to hematologists around the world. Accordingly, the Society has transitioned the ASH Meeting on Hematologic Malignancies (MHM) to a virtual experience that will combine both live and on-demand sessions, providing an opportunity for attendees to be part of an educational experience featuring leading experts, up-to-date clinical content, and opportunities for engagement.
The meeting will include on-demand sessions released between August 27 and September 10, live sessions discussing the impact of COVID-19 on hematologic malignancies, the classic “How I Treat” presentation format, and viewable content available to registered participants, even after the meeting concludes. ASH will also offer the ASH Consultative Hematology Course in conjunction with the MHM (special combination registration pricing will be available) as a virtual experience.
Register now and check for updates here.
LLS Clinical Trial Support Center Connects Patients to Blood Cancer Clinical Trials
With many studies on hold during the COVID-19 pandemic, patients still need guidance in finding appropriate clinical trials. ASH and the Leukemia & Lymphoma Society (LLS) Clinical Trial Support Center (CTSC) have collaborated to enhance access to LLS’s free service providing clinical trials navigation and support to health care professionals, and patients with blood cancer and their families, during a very challenging period.
Many cancer clinical trials continue to enroll patients despite COVID-19, and many patients are seeking help finding trials closer to home to avoid traveling. ASH member physicians and their care teams, along with patients and caregivers, receive one-on-one support from LLS’s CTSC Nurse Navigators and have direct access to them for the duration of the search and enrollment process, and while patients are on the trials. LLS’s Nurse Navigators play a critical role in investigating which trials are open and currently enrolling, and thus are needed now more than even to provide direction.
Visit the ASH website for more information.
Two Communicator Awards for ASH Clinical News
ASH Clinical News (ACN) is proud to be the recipient of two 2020 Communicator Awards of Distinction from the Academy of Interactive and Visual Arts!
The first award was presented for a Blood Beyond Borders feature article published in the magazine’s August 2019 issue, “Israel and Palestine Find Common Ground in Blood Services,” by freelance writer Debra L. Beck. The article incorporated perspectives from people on both sides of the conflict to show how medical care and preserving life with blood products transcends borders.
The second award was given to the final editorial of past ACN editor-in-chief Mikkael Sekeres, MD, MS, titled “My Patients, My Lanes.” In this Editor’s Corner, published in the December 2019 issue, Dr. Sekeres defined the lanes of his “health-care highway” – the issues about which he feels he has a professional, moral, and ethical obligation to have an opinion.
These achievements are due in large part to readers’ enthusiastic response to the content we provide. Thank you for your continued engagement and support of this publication!